Skip to main content
Sign inGet started
Back to all tickers

Azitra, Inc. (AZTR) stock forecast & analysis

0.7692

NYSE American · USD

Up: +0.0121, +1.6%

0.7300Down: -0.0392, -5.1%

1 analysis

Use Arrow keys to explore price history; Home and End jump to the oldest and newest points
Price history for AZTR.US from 10-01 08:00 to 10-30 23:57 with 1 analysis run marked; public runs are shown as stance-colored dots (Bullish, Bearish, or Neutral) and gated runs as a lock icon (sign in to read). Each marker is a link to sign in.BullishBearishNeutralLocked · sign in to read

Latest analysis: · verdict locked

Open
0.7120
Previous close
0.7571
Day range
0.6511 – 0.7899
52-week range
0.5200 – 5.59
Volume (shares)
774.01K
Net assets
Not available
Expense ratio
Not available
Shares outstanding
6.06M
P/E ratio
Not available
Dividend yield
0.00%
Beta
-1.04
Market cap
4.66M
Market Scanner’s AI analysis of Azitra, Inc. (AZTR), updated October 2026: Azitra's recent analyses covered positive clinical trial data and a reverse stock split, alongside mixed technical indicators and consistent net losses.

This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Azitra, Inc. (AZTR) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.

Summary

Azitra's recent analyses covered positive clinical trial data and a reverse stock split, alongside mixed technical indicators and consistent net losses.

Recent analyses for Azitra, Inc. (AZTR) examined positive developments in its clinical trials, including promising ex vivo study results for ATR-COSF and the advancement of the ATR-04 Phase 1/2 trial. The reports also noted a recent reverse stock split and mixed short-term and long-term technical trends for the stock. The company's financial performance consistently showed net losses and minimal revenue in recent reporting periods.

AZTR news & sentiment

News headlines highlighted positive clinical trial developments and a reverse stock split. Social media discussion indicated mixed sentiment, with some users expressing optimism about trial progress while others voiced concerns regarding the stock split and recent price action.

AZTR technical picture

The AZTR stock showed mixed short-term and long-term trends, with upward short-term momentum indicated by price action above the 10-day EMA. However, the price remained below the 50-day and 200-day SMAs, suggesting bearish medium and long-term trends. Momentum readings from the RSI were approaching overbought territory, while the MFI indicated strong buying pressure. MACD readings were below zero, suggesting bearish momentum.

Fundamentals

Azitra, Inc. has consistently reported net losses and minimal total revenue in recent annual and quarterly periods. As of June 30, 2026, the company's total assets were valued at $8.9 million, with total liabilities at $1.6 million, resulting in positive shareholder equity.

Factors discussed — upside

  • Positive ex vivo study results for ATR-COSF showing improvements in skin elasticity and reduction of fine lines.
  • Advancement of the ATR-04 Phase 1/2 clinical trial to cohort 2 after a safety review.
  • Updated valuation reflecting potential of cosmetic and EGFRi rash programs.
  • Stock price above 10-day EMA indicating upward short-term momentum.
  • RSI approaching overbought territory suggesting room for upward movement.

Factors discussed — risks

  • Consistent net losses reported in annual and quarterly income statements.
  • Minimal total revenue reported in recent annual periods.
  • Stock price below 50-day SMA and significantly below 200-day SMA, indicating bearish medium and long-term trends.
  • MACD below zero indicating bearish momentum.
  • Reverse stock split announced, which can be perceived negatively by the market.
  • Clinical trial progress
  • Financial performance
  • Technical indicators
  • Corporate actions

Summary updated .

AZTR technical indicators

Common technical indicators for AZTR, computed from its daily closing prices.

IndicatorValueReading
50-day simple moving average1.38Price below
10-day exponential moving average0.90Price below
Relative strength index (14-day)40.65Neutral
MACD line (12/26/9)-0.1452Above its signal line
Bollinger bands (20-day, 2σ)0.39 – 1.54Price inside the bands

Analyses

Recent AZTR.US analyses are locked — sign in to read them or generate a fresh one.

CaseDescriptionDate

Frequently asked questions

What is the bull case for Azitra, Inc.?
The bull case for Azitra, Inc. centers on promising clinical trial developments, including positive ex vivo study results for ATR-COSF and the advancement of the ATR-04 Phase 1/2 trial. An updated valuation reflects the potential of its cosmetic and EGFRi rash programs, supported by short-term technical indicators showing upward momentum.
What are the risks for Azitra, Inc.?
Risks for Azitra, Inc. include consistent net losses and minimal revenue reported in recent financial periods. The stock's technical indicators show bearish medium and long-term trends, with a MACD below zero. Additionally, a recently announced reverse stock split may be perceived negatively by the market.
Is Azitra, Inc. bullish or bearish?
Recent AI analyses of Azitra, Inc. examined factors on both sides. Discussed upside: The bull case for Azitra, Inc. centers on promising clinical trial developments, including positive ex vivo study results for ATR-COSF and the advancement of the ATR-04 Phase 1/2 trial. An updated valuation reflects the potential of its cosmetic and EGFRi rash programs, supported by short-term technical indicators showing upward momentum. Discussed risks: Risks for Azitra, Inc. include consistent net losses and minimal revenue reported in recent financial periods. The stock's technical indicators show bearish medium and long-term trends, with a MACD below zero. Additionally, a recently announced reverse stock split may be perceived negatively by the market. These are descriptive observations, not a recommendation.
What is the latest sentiment on Azitra, Inc.?
News headlines highlighted positive clinical trial developments and a reverse stock split. Social media discussion indicated mixed sentiment, with some users expressing optimism about trial progress while others voiced concerns regarding the stock split and recent price action.
How does Market Scanner analyse Azitra, Inc.?
Every analysis of Azitra, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
What is the bull case for Azitra, Inc.?

The bull case for Azitra, Inc. centers on promising clinical trial developments, including positive ex vivo study results for ATR-COSF and the advancement of the ATR-04 Phase 1/2 trial. An updated valuation reflects the potential of its cosmetic and EGFRi rash programs, supported by short-term technical indicators showing upward momentum.

What are the risks for Azitra, Inc.?

Risks for Azitra, Inc. include consistent net losses and minimal revenue reported in recent financial periods. The stock's technical indicators show bearish medium and long-term trends, with a MACD below zero. Additionally, a recently announced reverse stock split may be perceived negatively by the market.

Is Azitra, Inc. bullish or bearish?

Recent AI analyses of Azitra, Inc. examined factors on both sides. Discussed upside: The bull case for Azitra, Inc. centers on promising clinical trial developments, including positive ex vivo study results for ATR-COSF and the advancement of the ATR-04 Phase 1/2 trial. An updated valuation reflects the potential of its cosmetic and EGFRi rash programs, supported by short-term technical indicators showing upward momentum. Discussed risks: Risks for Azitra, Inc. include consistent net losses and minimal revenue reported in recent financial periods. The stock's technical indicators show bearish medium and long-term trends, with a MACD below zero. Additionally, a recently announced reverse stock split may be perceived negatively by the market. These are descriptive observations, not a recommendation.

What is the latest sentiment on Azitra, Inc.?

News headlines highlighted positive clinical trial developments and a reverse stock split. Social media discussion indicated mixed sentiment, with some users expressing optimism about trial progress while others voiced concerns regarding the stock split and recent price action.

How does Market Scanner analyse Azitra, Inc.?

Every analysis of Azitra, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.

Read the methodology
Bundles used
gemini-low-v2

Run a fresh AZTR.US analysis

Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.

Or read 1 earlier report

Most analyzed tickers